 |
41 Diseases |  |
16 Trials |
|
16 Trials |  |
501 News |  |
| «12345678» |
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open: SOMACROL: Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects (clinicaltrials.gov) - Jul 29, 2016
P=N/A, N=150, Recruiting, Sponsor: Ipsen
Not yet recruiting --> Recruiting
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open, Combination therapy: PRELUDE: A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel (clinicaltrials.gov) - Jul 29, 2016
P=N/A, N=150, Recruiting, Sponsor: Ipsen
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open, Combination therapy: ATLANT: Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. (clinicaltrials.gov) - Jul 29, 2016
P2, N=40, Recruiting, Sponsor: Ipsen
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New trial, Combination therapy, Metastases: The MetNET-2 Trial (clinicaltrials.gov) - Jul 6, 2016
P0, N=20, Recruiting, Sponsor: Melani Cecilia
- ||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment closed, Trial primary completion date: LANTERN: Efficacy and Safety of Lanreotide Autogel (clinicaltrials.gov) - Jul 1, 2016
P3, N=128, Active, not recruiting, Sponsor: Ipsen
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> Nov 2016
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New trial: SOMACROL: Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects (clinicaltrials.gov) - Jun 21, 2016
P=N/A, N=150, Not yet recruiting, Sponsor: Ipsen
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New trial, Combination therapy: PRELUDE: A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel (clinicaltrials.gov) - Jun 2, 2016
P=N/A, N=150, Not yet recruiting, Sponsor: Ipsen
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion: SODA: Somatuline (clinicaltrials.gov) - May 31, 2016
P=N/A, N=260, Completed, Sponsor: Ipsen
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> Nov 2016 Active, not recruiting --> Completed
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial primary completion date: Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly (clinicaltrials.gov) - May 31, 2016
P2a, N=27, Recruiting, Sponsor: Ipsen
Active, not recruiting --> Completed Trial primary completion date: Feb 2017 --> Jun 2018
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial primary completion date, HEOR, Combination therapy: QoL in IMBO: Quality of Life in Patients With Inoperable Malignant Bowel Obstruction (clinicaltrials.gov) - May 31, 2016
P2, N=84, Recruiting, Sponsor: Ipsen
Trial primary completion date: Feb 2017 --> Jun 2018 Trial primary completion date: Mar 2016 --> Mar 2017
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial primary completion date: IMIO: Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction (clinicaltrials.gov) - May 31, 2016
P2, N=50, Recruiting, Sponsor: Ipsen
Trial primary completion date: Mar 2016 --> Mar 2017 Trial primary completion date: Mar 2016 --> Mar 2017
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial primary completion date, Circulating tumor cells, Tumor cell: CALM-NET: Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients (clinicaltrials.gov) - May 31, 2016
P4, N=50, Recruiting, Sponsor: Ipsen
Trial primary completion date: Mar 2016 --> Mar 2017 Trial primary completion date: May 2017 --> Jun 2016
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment closed, HEOR: ACRO QLQ: Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel (clinicaltrials.gov) - May 31, 2016
P=N/A, N=150, Active, not recruiting, Sponsor: Ipsen
Trial primary completion date: May 2017 --> Jun 2016 Recruiting --> Active, not recruiting
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New trial, Metastases: Community-based Neuroendocrine Tumor (NET) Research Study (clinicaltrials.gov) - Apr 6, 2016
P=N/A, N=100, Recruiting, Sponsor: Ipsen
- |||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open, Metastases: SPINET: Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours (clinicaltrials.gov) - Apr 1, 2016
P3, N=216, Recruiting, Sponsor: Ipsen
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion, Enrollment change, Trial primary completion date, Surgery: A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. (clinicaltrials.gov) - Mar 16, 2016
P4, N=4, Completed, Sponsor: John Wayne Cancer Institute
Not yet recruiting --> Recruiting Recruiting --> Completed | N=24 --> 4 | Trial primary completion date: Sep 2016 --> Jan 2016
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New trial: ACRO-OPTIM: Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg (clinicaltrials.gov) - Mar 4, 2016
P=N/A, N=183, Recruiting, Sponsor: Ipsen
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New P2 trial, Combination therapy: ATLANT: Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. (clinicaltrials.gov) - Mar 4, 2016
P2, N=40, Not yet recruiting, Sponsor: Ipsen
- ||||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion: NET729: Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour (clinicaltrials.gov) - Mar 1, 2016
P3, N=89, Completed, Sponsor: Ipsen
Recruiting --> Completed | N=24 --> 4 | Trial primary completion date: Sep 2016 --> Jan 2016 Active, not recruiting --> Completed
- |||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial primary completion date: LANTERN: Efficacy and Safety of Lanreotide Autogel (clinicaltrials.gov) - Mar 1, 2016
P3, N=118, Recruiting, Sponsor: Ipsen
Active, not recruiting --> Completed Trial primary completion date: Jul 2017 --> Feb 2017
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial primary completion date: Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly (clinicaltrials.gov) - Mar 1, 2016
P2a, N=27, Recruiting, Sponsor: Ipsen
Trial primary completion date: Jul 2017 --> Feb 2017 Trial primary completion date: Apr 2016 --> Feb 2017
- |||||||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New P3 trial, Metastases: SPINET: Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours (clinicaltrials.gov) - Feb 17, 2016
P3, N=216, Not yet recruiting, Sponsor: Ipsen
- ||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
New P2 trial, Metastases: CLARINET FORTE: Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel (clinicaltrials.gov) - Jan 11, 2016
P2, N=100, Recruiting, Sponsor: Ipsen
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment closed, Enrollment change: SODA: Somatuline (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=260, Active, not recruiting, Sponsor: Ipsen
Trial primary completion date: Apr 2016 --> Feb 2017 Recruiting --> Active, not recruiting | N=200 --> 260
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment change: Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG) (clinicaltrials.gov) - Oct 1, 2015
P2, N=0, Withdrawn, Sponsor: Ipsen
Recruiting --> Active, not recruiting | N=200 --> 260 N=10 --> 0
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Biomarker, Enrollment change, Trial termination, Trial primary completion date: TAPAS: Predictive Factors Study (clinicaltrials.gov) - Sep 30, 2015
P=N/A, N=5, Terminated, Sponsor: Ipsen
N=10 --> 0 N=34 --> 5 | Recruiting --> Terminated | Trial primary completion date: Aug 2019 --> Sep 2015; Poor enrolment
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Biomarker, Enrollment closed: SOPRANo: Somatuline Predictive Factors in Acromegaly and NET (clinicaltrials.gov) - Sep 30, 2015
P=N/A, N=152, Active, not recruiting, Sponsor: Ipsen
N=34 --> 5 | Recruiting --> Terminated | Trial primary completion date: Aug 2019 --> Sep 2015; Poor enrolment Recruiting --> Active, not recruiting
- |||||||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New P3 trial: LANTERN: Efficacy and Safety of Lanreotide Autogel (clinicaltrials.gov) - Jul 9, 2015
P3, N=118, Recruiting, Sponsor: Ipsen
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial primary completion date: SODA: Somatuline (clinicaltrials.gov) - Jul 1, 2015
P=N/A, N=200, Recruiting, Sponsor: Ipsen
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Dec 2015
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial primary completion date, Circulating tumor cells, Tumor cell: CALM-NET: Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients (clinicaltrials.gov) - Jun 30, 2015
P4, N=50, Recruiting, Sponsor: Ipsen
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Apr 2016 --> Apr 2017
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial primary completion date: Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma (clinicaltrials.gov) - Jun 11, 2015
P3, N=50, Recruiting, Sponsor: University Hospital, Ghent
Trial primary completion date: Apr 2016 --> Apr 2017 Trial primary completion date: Dec 2014 --> Dec 2015
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment closed, Trial primary completion date: DIPAK1: Study of Lanreotide to Treat Polycystic Kidney Disease (clinicaltrials.gov) - May 28, 2015
P3, N=300, Active, not recruiting, Sponsor: University Medical Centre Groningen
Trial primary completion date: Dec 2014 --> Dec 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Aug 2017
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open: Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly (clinicaltrials.gov) - Apr 25, 2015
P2a, N=27, Recruiting, Sponsor: Ipsen
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Aug 2017 Not yet recruiting --> Recruiting
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
HEOR: ACRO QLQ: Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel (clinicaltrials.gov) - Mar 26, 2015
P=N/A, N=150, Recruiting, Sponsor: Ipsen
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New P2a trial, New P3 trial: Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly (clinicaltrials.gov) - Mar 24, 2015
P2a, N=27, Not yet recruiting, Sponsor: Ipsen
- ||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New P2 trial, HEOR, Combination therapy: QoL in IMBO: Quality of Life in Patients With Inoperable Malignant Bowel Obstruction (clinicaltrials.gov) - Feb 19, 2015
P2, N=84, Recruiting, Sponsor: Ipsen
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial primary completion date: Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma (clinicaltrials.gov) - Dec 6, 2014
P3, N=50, Recruiting, Sponsor: University Hospital, Ghent
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2013 --> Dec 2014
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion: Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients (clinicaltrials.gov) - Dec 6, 2014
P2, N=40, Completed, Sponsor: University Hospital, Ghent
Trial primary completion date: Dec 2013 --> Dec 2014 Recruiting --> Completed
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open: SONNET: Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET (clinicaltrials.gov) - Nov 4, 2014
P2, N=40, Recruiting, Sponsor: Ipsen
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open: IMIO: Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction (clinicaltrials.gov) - Oct 30, 2014
P2, N=50, Recruiting, Sponsor: Ipsen
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New P2 trial: IMIO: Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction (clinicaltrials.gov) - Oct 27, 2014
P2, N=50, Not yet recruiting, Sponsor: Ipsen
- |||| Signifor LAR (pasireotide long acting release) / Recordati, Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial primary completion date: PAOLA: Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly (clinicaltrials.gov) - Oct 23, 2014
P3, N=190, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2015 --> Jan 2013
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New P2 trial: SONNET: Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET (clinicaltrials.gov) - Sep 5, 2014
P2, N=40, Not yet recruiting, Sponsor: Ipsen
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Biomarker, Enrollment open: TAPAS: Predictive Factors Study (clinicaltrials.gov) - Aug 22, 2014
P=N/A, N=34, Recruiting, Sponsor: Ipsen
Trial primary completion date: Dec 2015 --> Jan 2013 Not yet recruiting --> Recruiting
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion, HEOR: Study in Polish Acromegalic Patients Treated With Somatuline Autogel (clinicaltrials.gov) - Aug 22, 2014
P=N/A, N=150, Completed, Sponsor: Ipsen
Not yet recruiting --> Recruiting Enrolling by invitation --> Completed
- | Somavert (pegvisomant) / Pfizer, Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, octreotide acetate / Generic mfg.
New P4 trial: Evaluation of a treatment regimen for acromegaly (EUDRACT) - Aug 7, 2014
P4, N=100, Ongoing, Sponsor:
- |||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial primary completion date: LOCKCYST: Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease (clinicaltrials.gov) - Jul 8, 2014
P2/3, N=59, Completed, Sponsor: Universitaire Ziekenhuizen Leuven
Enrolling by invitation --> Completed Trial primary completion date: Feb 2013 --> Jul 2014
- ||||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion, Trial primary completion date: LOCKCYST: Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease (clinicaltrials.gov) - Jul 8, 2014
P2/3, N=59, Completed, Sponsor: Universitaire Ziekenhuizen Leuven
Trial primary completion date: Feb 2013 --> Jul 2014 Recruiting --> Completed | Trial primary completion date: Feb 2013 --> Jul 2014
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Biomarker, Trial primary completion date: TAPAS: Predictive Factors Study (clinicaltrials.gov) - Jul 2, 2014
P=N/A, N=34, Not yet recruiting, Sponsor: Ipsen
Recruiting --> Completed | Trial primary completion date: Feb 2013 --> Jul 2014 Trial primary completion date: Feb 2019 --> Jul 2019
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Biomarker, Trial initiation date: TAPAS: Predictive Factors Study (clinicaltrials.gov) - Apr 28, 2014
P=N/A, N=34, Not yet recruiting, Sponsor: Ipsen
Trial primary completion date: Feb 2019 --> Jul 2019 Initiation date: Mar 2014 --> May 2014